These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 25014290)
21. Nanotechnology and public health. Matsudai M; Hunt G Nihon Koshu Eisei Zasshi; 2005 Nov; 52(11):923-7. PubMed ID: 16408476 [TBL] [Abstract][Full Text] [Related]
22. A qualitative exploration of the major challenges facing pharmacovigilance in Saudi Arabia. Aljadhey H; Mahmoud MA; Alshammari TM; Al-Dhaeefi M; Le Louet H; Perez-Gutthann S; Pitts PJ Saudi Med J; 2015 Sep; 36(9):1097-102. PubMed ID: 26318468 [TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation. Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547 [TBL] [Abstract][Full Text] [Related]
24. Comparisons of Food and Drug Administration and European Medicines Agency risk management implementation for recent pharmaceutical approvals: report of the International Society for Pharmacoeconomics and outcomes research risk benefit management working group. Lis Y; Roberts MH; Kamble S; J Guo J; Raisch DW Value Health; 2012 Dec; 15(8):1108-18. PubMed ID: 23244814 [TBL] [Abstract][Full Text] [Related]
25. [The use of nanotechnology in medicinal products in the light of European Union law]. Jurewicz M Pol Merkur Lekarski; 2014 Dec; 37(222):369-72. PubMed ID: 25715580 [TBL] [Abstract][Full Text] [Related]
26. Packaging of pharmaceuticals: still too many dangers but several encouraging initiatives. Prescrire Int; 2007 Jun; 16(89):126-8. PubMed ID: 17585428 [TBL] [Abstract][Full Text] [Related]
27. [Public health benefits of non prescription medicines and self care]. Baumelou A Bull Acad Natl Med; 2007 Nov; 191(8):1527-31. PubMed ID: 18666454 [TBL] [Abstract][Full Text] [Related]
28. Pharmacovigilance in Israel - tools, processes, and actions. Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141 [TBL] [Abstract][Full Text] [Related]
29. Medication safety knowledge, attitudes and practices among community pharmacists in Lebanon. Hajj A; Hallit S; Ramia E; Salameh P; Curr Med Res Opin; 2018 Jan; 34(1):149-156. PubMed ID: 28758813 [TBL] [Abstract][Full Text] [Related]
30. Biosimilars in psoriasis: Clinical practice and regulatory perspectives in Latin America. de la Cruz C; de Carvalho AV; Dorantes GL; Londoño Garcia AM; Gonzalez C; Maskin M; Podoswa N; Redfern JS; Valenzuela F; van der Walt J; Romiti R J Dermatol; 2017 Jan; 44(1):3-12. PubMed ID: 27461455 [TBL] [Abstract][Full Text] [Related]
31. [Construction of the Brazilian Sanitary Surveillance System: arguments to debate]. De Seta MH; Dain S Cien Saude Colet; 2010 Nov; 15 Suppl 3():3307-17. PubMed ID: 21120315 [TBL] [Abstract][Full Text] [Related]
32. How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities. Tyner KM; Zheng N; Choi S; Xu X; Zou P; Jiang W; Guo C; Cruz CN AAPS J; 2017 Jul; 19(4):1071-1083. PubMed ID: 28421428 [TBL] [Abstract][Full Text] [Related]
33. [The new pharmacovigilance legislation in practice]. Broekmans AW; Mol PG Ned Tijdschr Geneeskd; 2014; 158():A7129. PubMed ID: 24846112 [TBL] [Abstract][Full Text] [Related]
34. Miracle drug: Brazil approves never-tested cancer medicine. Kuchenbecker RS; Mota DM J Oncol Pharm Pract; 2017 Jul; 23(5):399-400. PubMed ID: 27566738 [TBL] [Abstract][Full Text] [Related]
35. Nanosilver and global public health: international regulatory issues. Faunce T; Watal A Nanomedicine (Lond); 2010 Jun; 5(4):617-32. PubMed ID: 20528456 [TBL] [Abstract][Full Text] [Related]
36. Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations. Ribeiro A; Lima S; Zampieri ME; Peinado M; Figueras A Expert Opin Drug Saf; 2017 Dec; 16(12):1329-1334. PubMed ID: 28817316 [TBL] [Abstract][Full Text] [Related]
37. Post-approval Studies for Rare Disease Treatments and Orphan Drugs. Maier WC; Christensen RA; Anderson P Adv Exp Med Biol; 2017; 1031():197-205. PubMed ID: 29214573 [TBL] [Abstract][Full Text] [Related]
38. The use of biosimilar medicines in oncology - position statement of the Brazilian Society of Clinical Oncology (SBOC). Fernandes GS; Sternberg C; Lopes G; Chammas R; Gifoni MAC; Gil RA; Araujo DV Braz J Med Biol Res; 2018 Jan; 51(3):e7214. PubMed ID: 29340530 [TBL] [Abstract][Full Text] [Related]
39. Heparin pharmacovigilance in Brazil. Junqueira DR; Viana TG; Peixoto ER; Barros FC; Carvalho Md; Perini E Rev Assoc Med Bras (1992); 2011; 57(3):322-6. PubMed ID: 21691698 [TBL] [Abstract][Full Text] [Related]
40. A global regulatory science agenda for vaccines. Elmgren L; Li X; Wilson C; Ball R; Wang J; Cichutek K; Pfleiderer M; Kato A; Cavaleri M; Southern J; Jivapaisarnpong T; Minor P; Griffiths E; Sohn Y; Wood D Vaccine; 2013 Apr; 31 Suppl 2():B163-75. PubMed ID: 23598478 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]